News
OCX
2.480
+1.64%
0.040
Oncocyte Price Target Raised to $4.25/Share From $3.60 by Needham
Dow Jones · 2d ago
Oncocyte Is Maintained at Buy by Needham
Dow Jones · 2d ago
Needham Maintains Buy on OncoCyte, Raises Price Target to $4.25
Benzinga · 2d ago
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
TipRanks · 2d ago
ONCOCYTE CORP <OCX.O>: NEEDHAM RAISES TARGET PRICE TO $4.25 FROM $3.60
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Airbnb, American Express, Mattel
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. American Express Co, Mattel and Amazon.com among those revised. Analysts raise target prices for American Express, Amazon, Fiserv and other companies. Airbnb, American Express and Mattel raise to buy from Mizuho.
Reuters · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. Nuwellis shares increased by 24.1% and VolitionRX stock increased by 16.66% during the same time period. Losers Abeona Therapeutics and OncoCyte stock declined by 45.7% and 16.34% respectively.
Benzinga · 3d ago
BIO-RAD LABORATORIES INC REPORTS 8.99% PASSIVE STAKE IN ONCOCYTE CORP AS OF APRIL 15 - SEC FILING
Reuters · 4d ago
Weekly Report: what happened at OCX last week (0415-0419)?
Weekly Report · 4d ago
Oncocyte Price Target Maintained With a $4.00/Share by Stephens & Co.
Dow Jones · 04/17 14:26
Stephens & Co. Reiterates Equal-Weight on OncoCyte, Maintains $4 Price Target
Benzinga · 04/17 14:16
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.
Benzinga · 04/15 18:11
NXPL, MGRM and OCX among pre-market losers
U.S. Economy NXPL, MGRM and OCX among pre-market losers. Marinus Pharmaceuticals -74% provides update on the phase 3 RAISE trial. NextPlat Corp -19% as FDA puts Phase 1 schizophrenia study on hold.
Seeking Alpha · 04/15 12:21
Weekly Report: what happened at OCX last week (0408-0412)?
Weekly Report · 04/15 12:04
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Medical Properties Trust, Inc. Shares jumped 13.1% in today's pre-market trading. The company announced it sold its majority interest in Utah Hospitals. LendingClub Corporation is expected to report earnings for the first quarter 2024 after the closing bell on Tuesday. Allarity Therapeutics shares rose 51% to $3.17 in pre- market trading.
Benzinga · 04/15 09:45
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 04/12 20:31
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
OncoCyte reported results for the fourth quarter of 2023. The company reported earnings per share of -$2.18 and revenue of $314,000. This was below the analyst estimate for earnings of $1.14 and $320,000 in revenue.
Investorplace · 04/12 14:52
OncoCyte Corp reports results for the quarter ended in December - Earnings Summary
OncoCyte Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.12 per share. Revenue fell 72% to $314.00 thousand from a year ago. The average analyst rating on the company's shares is "hold"
Reuters · 04/12 13:31
S&P Futures Tick Lower as Investors Digest Big Bank Earnings
NASDAQ · 04/12 13:23
Top 3 Health Care Stocks That May Collapse In Q2
Three stocks in the health care sector are overbought as of April 12, 2024. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when they go down. An asset is typically considered to be overb bought when the RSI value is above 70.
Benzinga · 04/12 12:34
More
Webull provides a variety of real-time OCX stock news. You can receive the latest news about Oncocyte Corporation through multiple platforms. This information may help you make smarter investment decisions.
About OCX
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, and DetermaCNI. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor, combined with information from the wound response surrounding the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test.